Home > Insider Trading > Filing (0000947871-25-000636)

Filing Details

Accession Number:: 0000947871-25-000636
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-07-01 21:23:37
Reporting Period:: 2025-06-27

Filing Date:: 2025-07-01
Accepted Time:: 2025-07-01 21:23:37
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1626971	Corvus Pharmaceuticals Inc.	CRVS	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue 54Th Floor New York NY 10022		Yes	No	Yes	No
1615374	Orbimed Capital Gp V Llc	601 Lexington Avenue 54Th Floor New York NY 10022		Yes	No	Yes	No

Transaction Summary

Sold:	1,176,332 shares	Avg. Price: $4.16	Total Value: $4,891,894.26
Number of Shares After Transactions:	7,165,006 shares

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-06-27	1,397,684	$3.50	8,341,338	No	4	X	Indirect	See Footnotes
Common Stock	Disposition	2025-06-27	1,176,332	$4.16	7,165,006	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	X	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Warrants (right to buy)	Disposition	2025-06-27	1,397,684	$0.00	1,397,684	$3.50

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2025-04-29	2025-06-30	No	4	X	Indirect

Footnotes

On June 27, 2025, OrbiMed Private Investments V, LP ("OPI V") exercised common warrants ("Warrants") to purchase 1,397,684 shares of the Issuer's Common Stock for $3.50 per share. OPI V paid the exercise price on a cashless basis, resulting in the Issuer withholding 1,176,332 of the Warrant shares to pay the exercise price and issuing to OPI V the remaining 221,352 shares.
These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V.
This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.